These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 535019)

  • 1. [Hydroxylated vitamin D metabolites, therapeutical uses of 1-alpha-hydroxycholecalciferol (author's transl)].
    Vokrouhlická O; Horn V; Stĕpán J; Justová V; Erben J; Lachmanová J; Pacovský V
    Cas Lek Cesk; 1979 Nov; 118(46):1424-8. PubMed ID: 535019
    [No Abstract]   [Full Text] [Related]  

  • 2. [Renal osteodystrophy in two children : a comparison of the effects of 1 alpha-hydroxycholecalciferol (author's transl)].
    Chantraine JM; Davin JC; Lambrechts L; Heynen G
    Ann Endocrinol (Paris); 1979; 40(2):161-2. PubMed ID: 475307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of renal bone disease with 1-alpha hydroxycholecalciferol].
    Shasha SM; Vinaver J; Chaimovitz C; Mazor J; Better OS
    Harefuah; 1976 Jul; 91(1-2):16-7. PubMed ID: 964770
    [No Abstract]   [Full Text] [Related]  

  • 4. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF
    Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
    [No Abstract]   [Full Text] [Related]  

  • 5. The treatment of uraemic osteopathy. II. The effect of 5,6-trans-25-hydroxycholecalciferol in terminal renal failure.
    von Herrath D; Kraft D; Grigoleit H; Schaefer K
    Ger Med; 1973; 3(3-4):93-5. PubMed ID: 4803059
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of renal osteopathy with 5,6-trans-25-hydroxycholecalciferol (author's transl)].
    Kraft D; Schaefer K; Grigoleit HG; Offermann G; von Herrath D; Delling G
    Dtsch Med Wochenschr; 1979 Nov; 104(48):1706-10. PubMed ID: 520165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [1 alpha-hydroxycholecalciferol in treatment of renal osteodystrophy].
    Chalmers TM; Davie MW; Hunter JO; Szaz KF
    J Urol Nephrol (Paris); 1974 Dec; 80(12):981. PubMed ID: 4617778
    [No Abstract]   [Full Text] [Related]  

  • 8. [1 alpha-hydroxycholecalciferol treatment of a 2-year-old child with severe renal osteodystrophy].
    Hansen HE; Christensen MS; Nielsen HE; Johannsen A
    Ugeskr Laeger; 1978 Apr; 140(16):919-21. PubMed ID: 653843
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapy of uremic osteopathy. II. Effect of 5,6-trans-25-hydroxycholecalciferol in terminal kidney insufficiency].
    von Herrath D; Kraft D; Grigoleit HG; Schaefer K
    Dtsch Med Wochenschr; 1973 Jul; 98(28):1379-81. PubMed ID: 4197778
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of 1 alpha-hydroxycholecalciferol (1 alpha-OH-D3) and eel calcitonin derivative in experimental renal osteodystrophy].
    Minatoguchi T
    Nihon Jinzo Gakkai Shi; 1982 Oct; 24(10):1157-71. PubMed ID: 7161947
    [No Abstract]   [Full Text] [Related]  

  • 11. The investigation and treatment of renal osteodystrophy.
    Catto GR; MacLeod M; Pelc B; Kodicek E
    Proc Eur Dial Transplant Assoc; 1975; 11():473-80. PubMed ID: 1197272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptomatic renal osteodystrophy after renal transplantation: treatment with 1-alpha-hydroxycholecalciferol.
    Williams PS; Hillis AN; Carty AJ; Sells RA; Bone JM
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2227-8. PubMed ID: 3274500
    [No Abstract]   [Full Text] [Related]  

  • 13. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
    Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effect of 1alpha-hydroxycholecalciferol in children and adults with renal glomerular osteodystrophy.
    Henderson RG; Kanis JA; Ledingham JG; Oliver DO; Russel RG; Smith R; Walton RJ
    Calcif Tissue Res; 1976 Aug; 21 Suppl():221-5. PubMed ID: 782661
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effects of 1-alpha-hydroxyvitamin D 3 treatment of osteodystrophy in uremic patients treated with periodic hemodialysis].
    Palmieri P; Albertazzi A; Cappelli P; Di Paolo B
    G Clin Med; 1981 Jul; 62(7):443-60. PubMed ID: 7308629
    [No Abstract]   [Full Text] [Related]  

  • 16. Proceedings: The use of metabolically-active derivatives of vitamin D in rickets and osteomalacia due to renal glomerular failure.
    Smith R; Henderson RG; Russell RG
    J Bone Joint Surg Br; 1975 May; 57(2):247-8. PubMed ID: 1141297
    [No Abstract]   [Full Text] [Related]  

  • 17. The clinical investigation of 1 alpha-OH-D3 on hemodialyzed patients.
    Watanabe Y; Asai K; Okura T; Kawahara H; Sakamoto N
    Nagoya J Med Sci; 1982 Mar; 44(3-4):89-101. PubMed ID: 7110306
    [No Abstract]   [Full Text] [Related]  

  • 18. [Long-term treatment of renalosteodystrophy with 1 alpha-hydroxycholecalciferol].
    Marco Franco JE; Alarcón Zurita A; Pizá Buñola C; Morey Molina A; Bestard Palmer J; Mairata Bosch S; Dalmau Diana M
    Rev Clin Esp; 1982 Jan; 164(1):33-5. PubMed ID: 7071401
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of whole body and regional assessments of calcium balance in renal osteodystrophy in the response to 1 alpha-hydroxy vitamin D3.
    Naik RB; Robertson PW; Robinson BH; Dabek JT; James HM; Kanis JA
    Proc Eur Dial Transplant Assoc; 1977; 14():425-32. PubMed ID: 600960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose vitamin D analogues for renal osteodystrophy.
    Lancet; 1989 Jun; 1(8651):1364-5. PubMed ID: 2567378
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.